12/7/2023 0 Comments Ivi international inc![]() ![]() Ogra, University of Texas/State University of New York (2003-2014)ĭr. John La Montagne, National Institute of Allergy and Infectious Diseases (2001) Longini, Jr., University of Washington (2007-2010)ĭr. Tim Endy, Department Chair, SUNY Upstate Medical University (2016) Black, Johns Hopkins Bloomberg School of Public Health (2001- 2014)ĭr. Theodore Tsai, Head of Immunization Science and Policy, Takeda Vaccines (2021- Present) Professor Mathuram Santosham, Johns Hopkins Bloomberg School of Public Health (2016- Present) Nahm, University of Alabama at Birmingham (2001- Present) Professor Myron “Mike” Levine, University of Maryland School of Medicine (2016- Present) Koup, National Institutes of Health (2016- Present) Glass, National Institutes of Health (2016-2020)ĭr. Susan Barnett, Senior Program Officer- HIV Vaccines, Bill & Melinda Gates Foundation (2021- Present)ĭr. Ahonkhai, Gwynedd Consultancy Group LLC (2018- Present) Mandl, Vaccines and Viral Vectors (2018- Present)ĭr. Siber, ClearPath Vaccines (2014-2019)Ĭhairperson Dr. Russell, Johns Hopkins Bloomberg School of Public Health (2003-2007)ĭr. Regina Rabinovich, Bill & Melinda Gates Foundation (2005-2007) George Poste, Arizona State University (2003-2006)ĭr. Mahmoud, Princeton University (2010-2017)ĭr. Joseph Kim, Inovio Pharmaceuticals (2014-2019) Professor Samuel Katz, Duke University Medical Center (2003-2007)ĭr. Maurice Hilleman, Merck Institute of Therapeutic Research (1995-1996) ![]() Glass, National Institutes of Health (2006-2011)ĭr. Chris Varma, Vision Medicines Inc./Frontier Medicines Corporation (2017- Present)Ĭhairperson Professor Barry R. Anthony Ford-Hutchinson, Chief Science Officer, RiboNova Inc. Clemens, Senior Scientific Advisor (IVI Director General 2000-2010)Ĭhairperson George Bickerstaff, CRT Capital Group LLC/M.M. The Vienna office will be strengthened by the location of the IVI branch and the contribution of international organizations to value creation in Austria will be increased.Julia Lynch, M.D., Director of Cholera Programĭr. Kimm expressed that he is, "deeply thankful to the Federal Ministry for European and International Affairs of Austria for supporting the opening of this office." The Foreign Minister of Austria, Alexander Schallenberg, said, “Austria continues to live up to its reputation as a place of encounter and international dialogue, now also increasingly in the field of vaccine research. Jerome Kim, Director General of IVI, said, that he is "thrilled to share that IVI has launched its Austria Country Office in the country’s capital, well established in areas of international cooperation and eager to advance its growing R&D ecosystem."Īs well as IVI's Europe Regional Office in Stockholm, these two sites will generate grant proposals with local partners and mobilize collaborative vaccine R&D projects for global health. This new office signals a step forward for Austria's commitment to increase efforts in vaccine research and development and for IVI's determination to work closely with the Austrian government, the local research network, and the biomedical industry.ĭr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |